Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Popp

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Molecular Biology|March 24, 2005
Structural dynamics of the DnaK-peptide complexSimone Popp, Lars Packschies, Nicole Radzwill, et al.
Mabs|July 23, 2024
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapyPatrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, et al.
Science Translational Medicine|December 2, 2016
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2Natalia Arenas-Ramirez, Chao Zou, Simone Popp, et al.
Neuroscience Letters|September 20, 2017
ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157Dominik Feuerbach, Patrick Schindler, Carmen Barske, et al.
Nature Communications|February 15, 2025
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologiesJuraj Velcicky, Gregor Cremosnik, Clemens Scheufler, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Molecular Biology|March 24, 2005
Structural dynamics of the DnaK-peptide complexSimone Popp, Lars Packschies, Nicole Radzwill, et al.
Mabs|July 23, 2024
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapyPatrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, et al.
Science Translational Medicine|December 2, 2016
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2Natalia Arenas-Ramirez, Chao Zou, Simone Popp, et al.
Neuroscience Letters|September 20, 2017
ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157Dominik Feuerbach, Patrick Schindler, Carmen Barske, et al.
Nature Communications|February 15, 2025
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologiesJuraj Velcicky, Gregor Cremosnik, Clemens Scheufler, et al.
Pageof 1